C101 IPF: CLINICAL STUDIES, THERAPEUTICS, AND MORE II: Bronchoalveolar Lavage Fluid Cytokine Profiles In Idiopathic Pulmonary Fibrosis Patients May Define Distinct Prognostic Groups

While some IPF patients achieve stabilization on treatment, there is a group of patients with unevitable lung functions decline despite treatment. All patients were treated with antifibrotics (pirfenidon or nintedanib according to reimbursement rules of health care provider) and LF were recorded 6 m...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of respiratory and critical care medicine 2017-01, Vol.195
Hauptverfasser:	Sterclova, M, Smetakova, M, Skibova, J, Vasakova, M
Format:	Artikel
Sprache:	eng
Schlagworte:	Biomarkers Cytokines Medical prognosis Pulmonary fibrosis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page
container_issue
container_start_page
container_title	American journal of respiratory and critical care medicine
container_volume	195
creator	Sterclova, M Smetakova, M Skibova, J Vasakova, M
description	While some IPF patients achieve stabilization on treatment, there is a group of patients with unevitable lung functions decline despite treatment. All patients were treated with antifibrotics (pirfenidon or nintedanib according to reimbursement rules of health care provider) and LF were recorded 6 month after IPF diagnosis.
format	Article
fullrecord	<record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_1926718494</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1926718494</sourcerecordid><originalsourceid>FETCH-proquest_journals_19267184943</originalsourceid><addsrcrecordid>eNqNjN1KwzAcxYsoOD_e4Q_eWkjWzq67q2m7BbpZtg68G7FLt8yY1CQd9MF8PzvwAbw658f5uPJGeBJM_DCO0PXgURT4YRi_33p31p4QwuMpRiPvh2CEgZb5DEhBV5QkBWyqbUqzzTNUi2ydlNm2omSgZJXC8m2dAaUzeDVa1UfN5JlryQwU7MwOHHLZiT2Q3ulPoTiURjdCcgtUAd0L3TJ3FDWUnfzSipkecvFhtBUWSuYEV87CkvWQ8uayToV1QtXucnNQeoAa5kZ3rX3wbhomLX_803vvKc8qsvBbo787bt3upDujhmiH4_FLhKdhHAb_a_0CSr5gGw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1926718494</pqid></control><display><type>article</type><title>C101 IPF: CLINICAL STUDIES, THERAPEUTICS, AND MORE II: Bronchoalveolar Lavage Fluid Cytokine Profiles In Idiopathic Pulmonary Fibrosis Patients May Define Distinct Prognostic Groups</title><source>Journals@Ovid Complete</source><source>American Thoracic Society (ATS) Journals Online</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Sterclova, M ; Smetakova, M ; Skibova, J ; Vasakova, M</creator><creatorcontrib>Sterclova, M ; Smetakova, M ; Skibova, J ; Vasakova, M</creatorcontrib><description>While some IPF patients achieve stabilization on treatment, there is a group of patients with unevitable lung functions decline despite treatment. All patients were treated with antifibrotics (pirfenidon or nintedanib according to reimbursement rules of health care provider) and LF were recorded 6 month after IPF diagnosis.</description><identifier>ISSN: 1073-449X</identifier><identifier>EISSN: 1535-4970</identifier><language>eng</language><publisher>New York: American Thoracic Society</publisher><subject>Biomarkers ; Cytokines ; Medical prognosis ; Pulmonary fibrosis</subject><ispartof>American journal of respiratory and critical care medicine, 2017-01, Vol.195</ispartof><rights>Copyright American Thoracic Society 2017</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids></links><search><creatorcontrib>Sterclova, M</creatorcontrib><creatorcontrib>Smetakova, M</creatorcontrib><creatorcontrib>Skibova, J</creatorcontrib><creatorcontrib>Vasakova, M</creatorcontrib><title>C101 IPF: CLINICAL STUDIES, THERAPEUTICS, AND MORE II: Bronchoalveolar Lavage Fluid Cytokine Profiles In Idiopathic Pulmonary Fibrosis Patients May Define Distinct Prognostic Groups</title><title>American journal of respiratory and critical care medicine</title><description>While some IPF patients achieve stabilization on treatment, there is a group of patients with unevitable lung functions decline despite treatment. All patients were treated with antifibrotics (pirfenidon or nintedanib according to reimbursement rules of health care provider) and LF were recorded 6 month after IPF diagnosis.</description><subject>Biomarkers</subject><subject>Cytokines</subject><subject>Medical prognosis</subject><subject>Pulmonary fibrosis</subject><issn>1073-449X</issn><issn>1535-4970</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqNjN1KwzAcxYsoOD_e4Q_eWkjWzq67q2m7BbpZtg68G7FLt8yY1CQd9MF8PzvwAbw658f5uPJGeBJM_DCO0PXgURT4YRi_33p31p4QwuMpRiPvh2CEgZb5DEhBV5QkBWyqbUqzzTNUi2ydlNm2omSgZJXC8m2dAaUzeDVa1UfN5JlryQwU7MwOHHLZiT2Q3ulPoTiURjdCcgtUAd0L3TJ3FDWUnfzSipkecvFhtBUWSuYEV87CkvWQ8uayToV1QtXucnNQeoAa5kZ3rX3wbhomLX_803vvKc8qsvBbo787bt3upDujhmiH4_FLhKdhHAb_a_0CSr5gGw</recordid><startdate>20170101</startdate><enddate>20170101</enddate><creator>Sterclova, M</creator><creator>Smetakova, M</creator><creator>Skibova, J</creator><creator>Vasakova, M</creator><general>American Thoracic Society</general><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20170101</creationdate><title>C101 IPF: CLINICAL STUDIES, THERAPEUTICS, AND MORE II: Bronchoalveolar Lavage Fluid Cytokine Profiles In Idiopathic Pulmonary Fibrosis Patients May Define Distinct Prognostic Groups</title><author>Sterclova, M ; Smetakova, M ; Skibova, J ; Vasakova, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_19267184943</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Biomarkers</topic><topic>Cytokines</topic><topic>Medical prognosis</topic><topic>Pulmonary fibrosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sterclova, M</creatorcontrib><creatorcontrib>Smetakova, M</creatorcontrib><creatorcontrib>Skibova, J</creatorcontrib><creatorcontrib>Vasakova, M</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>American journal of respiratory and critical care medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sterclova, M</au><au>Smetakova, M</au><au>Skibova, J</au><au>Vasakova, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>C101 IPF: CLINICAL STUDIES, THERAPEUTICS, AND MORE II: Bronchoalveolar Lavage Fluid Cytokine Profiles In Idiopathic Pulmonary Fibrosis Patients May Define Distinct Prognostic Groups</atitle><jtitle>American journal of respiratory and critical care medicine</jtitle><date>2017-01-01</date><risdate>2017</risdate><volume>195</volume><issn>1073-449X</issn><eissn>1535-4970</eissn><abstract>While some IPF patients achieve stabilization on treatment, there is a group of patients with unevitable lung functions decline despite treatment. All patients were treated with antifibrotics (pirfenidon or nintedanib according to reimbursement rules of health care provider) and LF were recorded 6 month after IPF diagnosis.</abstract><cop>New York</cop><pub>American Thoracic Society</pub></addata></record>
fulltext	fulltext
identifier	ISSN: 1073-449X
ispartof	American journal of respiratory and critical care medicine, 2017-01, Vol.195
issn	1073-449X 1535-4970
language	eng
recordid	cdi_proquest_journals_1926718494
source	Journals@Ovid Complete; American Thoracic Society (ATS) Journals Online; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects	Biomarkers Cytokines Medical prognosis Pulmonary fibrosis
title	C101 IPF: CLINICAL STUDIES, THERAPEUTICS, AND MORE II: Bronchoalveolar Lavage Fluid Cytokine Profiles In Idiopathic Pulmonary Fibrosis Patients May Define Distinct Prognostic Groups
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T00%3A19%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=C101%20IPF:%20CLINICAL%20STUDIES,%20THERAPEUTICS,%20AND%20MORE%20II:%20Bronchoalveolar%20Lavage%20Fluid%20Cytokine%20Profiles%20In%20Idiopathic%20Pulmonary%20Fibrosis%20Patients%20May%20Define%20Distinct%20Prognostic%20Groups&rft.jtitle=American%20journal%20of%20respiratory%20and%20critical%20care%20medicine&rft.au=Sterclova,%20M&rft.date=2017-01-01&rft.volume=195&rft.issn=1073-449X&rft.eissn=1535-4970&rft_id=info:doi/&rft_dat=%3Cproquest%3E1926718494%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1926718494&rft_id=info:pmid/&rfr_iscdi=true